Exelixis Stock: Building On A Blockbuster (NASDAQ:EXEL)
Exelixis is a young commercial stage biopharma that is enjoying success with its CABOMETYX. Read more to see why I consider EXEL stock a near-term buy.
Daiichi Sankyo Bristol Myers Squibb Roche Group Pharmaceuticals Inc Cancer Therapy Evaluation Program Stage Compounds
Source: seekingalpha.com